Successful use of argatroban during the third trimester of pregnancy: Case report and review of the literature

Sallie K. Young, Hamid Al-Mondhiry, Sonia Vaida, Anthony Ambrose, John J. Botti

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Direct thrombin inhibitors are commonly used anticoagulants in patients with known or suspected heparin-induced thrombocytopenia (HIT). All three direct thrombin inhibitors available in the United States - argatroban, bivalirudin, and lepirudin - are pregnancy category B drugs based on animal studies, but little data are available on the safety of these agents during human pregnancy Whereas several case reports support the safe use of lepirudin, only one case report has been published with argatroban and none with bivalirudin. We describe a 26-year-old pregnant woman with portal vein thrombosis and thrombocytopenia treated with argatroban for possible HIT during her last trimester. An argatroban infusion was started at 2 pg/kg/minute during her 33rd week of pregnancy, with the dosage titrated based on the activated partial thromboplastin time; infusion rates ranged from 2-8 pg/kg/minute. Treatment continued until her 39th week of pregnancy, when labor was induced. Argatroban therapy was discontinued 7 hours before epidural anesthesia. The patient successfully delivered a healthy male newborn, devoid of any known adverse effects from argatroban. The infant was found to have a small ventricular septal defect and patent foramen ovale at birth, but it is unlikely that these were caused by argatroban since organogenesis occurs in the first trimester. Even though the cause of this patient's thrombocytopenia was later determined to be idiopathic thrombocytopenic purpura, this is an important case that adds to the literature on use of argatroban during pregnancy.

Original languageEnglish (US)
Pages (from-to)1531-1536
Number of pages6
JournalPharmacotherapy
Volume28
Issue number12
DOIs
StatePublished - Jan 1 2008

Fingerprint

Third Pregnancy Trimester
Thrombocytopenia
Pregnancy
Antithrombins
Heparin
Induced Labor
Patent Foramen Ovale
Idiopathic Thrombocytopenic Purpura
Organogenesis
Partial Thromboplastin Time
argatroban
Epidural Anesthesia
Ventricular Heart Septal Defects
First Pregnancy Trimester
Portal Vein
Anticoagulants
Pregnant Women
Thrombosis
Parturition
Newborn Infant

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

@article{8d2748abb16848858e9ac2db0ce2f110,
title = "Successful use of argatroban during the third trimester of pregnancy: Case report and review of the literature",
abstract = "Direct thrombin inhibitors are commonly used anticoagulants in patients with known or suspected heparin-induced thrombocytopenia (HIT). All three direct thrombin inhibitors available in the United States - argatroban, bivalirudin, and lepirudin - are pregnancy category B drugs based on animal studies, but little data are available on the safety of these agents during human pregnancy Whereas several case reports support the safe use of lepirudin, only one case report has been published with argatroban and none with bivalirudin. We describe a 26-year-old pregnant woman with portal vein thrombosis and thrombocytopenia treated with argatroban for possible HIT during her last trimester. An argatroban infusion was started at 2 pg/kg/minute during her 33rd week of pregnancy, with the dosage titrated based on the activated partial thromboplastin time; infusion rates ranged from 2-8 pg/kg/minute. Treatment continued until her 39th week of pregnancy, when labor was induced. Argatroban therapy was discontinued 7 hours before epidural anesthesia. The patient successfully delivered a healthy male newborn, devoid of any known adverse effects from argatroban. The infant was found to have a small ventricular septal defect and patent foramen ovale at birth, but it is unlikely that these were caused by argatroban since organogenesis occurs in the first trimester. Even though the cause of this patient's thrombocytopenia was later determined to be idiopathic thrombocytopenic purpura, this is an important case that adds to the literature on use of argatroban during pregnancy.",
author = "Young, {Sallie K.} and Hamid Al-Mondhiry and Sonia Vaida and Anthony Ambrose and Botti, {John J.}",
year = "2008",
month = "1",
day = "1",
doi = "10.1592/phco.28.12.1531",
language = "English (US)",
volume = "28",
pages = "1531--1536",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "12",

}

Successful use of argatroban during the third trimester of pregnancy : Case report and review of the literature. / Young, Sallie K.; Al-Mondhiry, Hamid; Vaida, Sonia; Ambrose, Anthony; Botti, John J.

In: Pharmacotherapy, Vol. 28, No. 12, 01.01.2008, p. 1531-1536.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Successful use of argatroban during the third trimester of pregnancy

T2 - Case report and review of the literature

AU - Young, Sallie K.

AU - Al-Mondhiry, Hamid

AU - Vaida, Sonia

AU - Ambrose, Anthony

AU - Botti, John J.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Direct thrombin inhibitors are commonly used anticoagulants in patients with known or suspected heparin-induced thrombocytopenia (HIT). All three direct thrombin inhibitors available in the United States - argatroban, bivalirudin, and lepirudin - are pregnancy category B drugs based on animal studies, but little data are available on the safety of these agents during human pregnancy Whereas several case reports support the safe use of lepirudin, only one case report has been published with argatroban and none with bivalirudin. We describe a 26-year-old pregnant woman with portal vein thrombosis and thrombocytopenia treated with argatroban for possible HIT during her last trimester. An argatroban infusion was started at 2 pg/kg/minute during her 33rd week of pregnancy, with the dosage titrated based on the activated partial thromboplastin time; infusion rates ranged from 2-8 pg/kg/minute. Treatment continued until her 39th week of pregnancy, when labor was induced. Argatroban therapy was discontinued 7 hours before epidural anesthesia. The patient successfully delivered a healthy male newborn, devoid of any known adverse effects from argatroban. The infant was found to have a small ventricular septal defect and patent foramen ovale at birth, but it is unlikely that these were caused by argatroban since organogenesis occurs in the first trimester. Even though the cause of this patient's thrombocytopenia was later determined to be idiopathic thrombocytopenic purpura, this is an important case that adds to the literature on use of argatroban during pregnancy.

AB - Direct thrombin inhibitors are commonly used anticoagulants in patients with known or suspected heparin-induced thrombocytopenia (HIT). All three direct thrombin inhibitors available in the United States - argatroban, bivalirudin, and lepirudin - are pregnancy category B drugs based on animal studies, but little data are available on the safety of these agents during human pregnancy Whereas several case reports support the safe use of lepirudin, only one case report has been published with argatroban and none with bivalirudin. We describe a 26-year-old pregnant woman with portal vein thrombosis and thrombocytopenia treated with argatroban for possible HIT during her last trimester. An argatroban infusion was started at 2 pg/kg/minute during her 33rd week of pregnancy, with the dosage titrated based on the activated partial thromboplastin time; infusion rates ranged from 2-8 pg/kg/minute. Treatment continued until her 39th week of pregnancy, when labor was induced. Argatroban therapy was discontinued 7 hours before epidural anesthesia. The patient successfully delivered a healthy male newborn, devoid of any known adverse effects from argatroban. The infant was found to have a small ventricular septal defect and patent foramen ovale at birth, but it is unlikely that these were caused by argatroban since organogenesis occurs in the first trimester. Even though the cause of this patient's thrombocytopenia was later determined to be idiopathic thrombocytopenic purpura, this is an important case that adds to the literature on use of argatroban during pregnancy.

UR - http://www.scopus.com/inward/record.url?scp=57149085866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57149085866&partnerID=8YFLogxK

U2 - 10.1592/phco.28.12.1531

DO - 10.1592/phco.28.12.1531

M3 - Article

C2 - 19025434

AN - SCOPUS:57149085866

VL - 28

SP - 1531

EP - 1536

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 12

ER -